Herantis Pharma Oyj (FI4000087861) — research page
FI · fi-cm-kg/FSME/FI4000087861 · as of 2026-11-06
Identity and listing
The issuer is Herantis Pharma Oyj, listed on First North Finland under ticker FI4000087861, with ISIN FI4000087861 and LEI 743700W4CQVYAT3WKK38. Its security type, segment, sector and jurisdiction are not on the record. Its listing status is listed, not halted.
| field | value | source · read date |
|---|---|---|
| name | Herantis Pharma Oyj | source · 2026-11-06 |
| exchange | First North Finland | source · 2026-11-06 |
| ticker | FI4000087861 | source · 2026-11-06 |
| ISIN | FI4000087861 | source · 2026-11-06 |
| LEI | 743700W4CQVYAT3WKK38 | source · 2026-11-06 |
| security type | not on the record | |
| segment | not on the record | |
| sector | not on the record | |
| jurisdiction | not on the record | |
| status | listed, not halted | source · 2026-11-09 |
The disclosure read
The record holds 31 filings on 27 filing days in the window 2025-11-06 to 2026-11-06. The median gap between filing days is 8.5 days. The latest filing is dated 2026-11-05, one day before the record date of 2026-11-06, and is of type Investor News. The First North Finland exchange median is 7.0 days cadence, 39.5 filings and 9.0 days latency across 48 issuers. The sector median is not on the record.
| filings | median gap between filing days | days from latest filing to as-of | |
|---|---|---|---|
| this issuer | 31 | 8.5 | 1 |
| exchange median: First North Finland (48 issuers) | 39.5 | 7 | 9 |
| date | type | category | filing |
|---|---|---|---|
| 2026-11-05 | Investor News | Investor News | Herantis Pharma: newly published clinical evidence validates HER-096 Phase 2 study design |
| 2026-10-28 | Other information disclosed according to the rules of the Exchange | Other information disclosed according to the rules of the Exchange | Composition of Herantis Pharma Plc's Shareholders' Nomination Committee |
| 2026-08-20 | Half year financial report | Half year financial report | Herantis Pharma releases 1H 2026 report today |
| 2026-08-10 | Investor News | Investor News | Herantis Pharma to publish financial statements for the first half of 2026 on August 20, 2026 - invitation to webcast presentation |
| 2026-07-31 | Major shareholder announcements | Major shareholder announcements | Herantis Pharma: Disclosure of Major Holdings according to Chapter 9, Section 10 of the Finnish Securities Markets Act |
window 2025-11-06 to 2026-11-06 · the node's disclosure lines, as get_filings serves them
Auditor
The auditor and its location are not on the record. The auditor changes are not on the record, as this register has no lifecycle type map yet.
Events and halts
Listing, delisting, name change, domicile change and segment move are not on the record, as this register has no lifecycle type map yet. The halt flag is listed, not halted.
Orderability
The outcome is not determinable, because the chapter's orderability section carries no client categories. The rule version is acm-68000/fi/mifid-ii-product-governance/r1, and the chapter is as of 2026-11-04.
rule acm-68000/fi/mifid-ii-product-governance/r1 · chapter as of 2026-11-04 · the full outcome: get_orderability
Coverage
The issuer's investor-relations page names 2 research houses: Edison Group and Inderes.
| research house | analyst | source · read date |
|---|---|---|
| Edison Group | issuer page · 2026-11-12 | |
| Inderes | Antti Siltanen | issuer page · 2026-11-12 |
Open research
The record holds 5 openly published research notes: Redeye, 2023-01-31; ABG Sundal Collier, 2021-02-09; Edison Investment Research, 2020-04-02; ABG Sundal Collier, 2020-02-25; and ABG Sundal Collier, 2020-02-04.
| date | publisher | note | kind |
|---|---|---|---|
| 2023-01-31 | Redeye | Redeye equity research update January of Herantis 2023 | independent |
| 2021-02-09 | ABG Sundal Collier | Herantis Pharma | independent |
| 2020-04-02 | Edison Investment Research | Funded to key data inflection points | issuer-sponsored |
| 2020-02-25 | ABG Sundal Collier | Herantis Pharma | independent |
| 2020-02-04 | ABG Sundal Collier | Herantis Pharma | issuer-sponsored |
Licensed
Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.
| licensor | entitlement | title | date | source |
|---|---|---|---|---|
| none loaded |
As-of depth
The market's vintage is not sealed. No issuer years are sealed, the market's earliest sealed date is not on the record, and the live record began is not on the record.
Sources
11 source pages are named on this page; every value above carries its own source page and read date in the numbers.
- 10.1
- https://firds.esma.europa.eu/firds/ (identity.exchange)
- 10.2
- https://mcp.fi-cm-kg.ai/events/FSME/FI4000087861 (the disclosure lines)
- 10.3
- https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=exchangeNewsFilterHEX|FirstNorthInformationHEX (the halt flag)
- 10.4
- https://fi.eu-cm-kg.ai/book/aio.json (the orderability chapter)
- 10.5
- https://herantis.com/investors/analyst-coverage/ (coverage)
- 10.6
- https://herantis.com/wp-content/uploads/2023/02/Redeye-equity-research-update-January-of-Herantis-2023-English.pdf (open research)
- 10.7
- https://herantis.com/wp-content/uploads/2021/02/ABG-in-depth-research-February-9.pdf (open research)
- 10.8
- https://herantis.com/wp-content/uploads/2020/04/Herantis-Pharma-Funded-to-key-data-inflection-points.pdf (open research)
- 10.9
- https://herantis.com/wp-content/uploads/2020/04/ABG_Impressions_from_capital_markets_day_2020-03-25.pdf (open research)
- 10.10
- https://herantis.com/wp-content/uploads/2020/02/ABG_Herantis_Initiation_2020-02-04.pdf (open research)
- 10.11
- https://mcp.fi-cm-kg.ai/record/FSME/FI4000087861 (the record)
Read it by agent
The same page, signed and receipted: get_research at https://mcp.getresearch.ai/mcp with {"isin":"FI4000087861"}. Twins: .md · .json. Written: Claude through the platform account, Haiku class; one pass; checked against the numbers. Page hash sha256:f751e6df23c92e53.